Recursion (NASDAQ: RXRX) has expanded its current strategic partnership with Bayer AG in Fibrosis. The expanded partnership includes Recursion’s robust inferential search abilities based on the growing human cellular biology maps that give Bayer the ability to advance further the work on its universe of proprietary fibrotic hypotheses.
Recursion and Bayer to collaborate on other fibrotic diseases
The companies may now collaborate on more than a dozen fibrotic disease-related projects. All programs will be subject to the previously agreed-upon economics, which could result in more than $100 million in commercial milestone payments and royalties on future sales for each potential program.
Inferential search allows Recursion to significantly expand the breadth and depth of the drug discovery space more efficiently, saving time and money while improving the process’ operationalization. The company will use the Recursion Map, a collection of actionable scientific insights derived from applying machine learning solutions to massive relatable datasets, to investigate hundreds of billions of biological relations spanning whole-genome genetic perturbations, several soluble factors, and pharmacological perturbations, as part of the expanded collaboration.
Inferential research key in fibrotic diseases study
Recursion CEO Chris Gibson said, “Our collaborations are centered around the goal of delivering better drugs to patients faster than we could on our own. At Recursion, we believe inferential search is the future of drug discovery and have made key advances in this space. We have a deep respect for and trust in our colleagues at Bayer and are looking forward to including these new tools in our collaboration and potentially expanding the number of programs we go after together – all for the benefit of patients.”
Bayer SVP and Head of Research and Early Development Philip Larsen said, “The speed and scale of progress made in a short period of time on a number of fibrotic disease models with our collaborators at Recursion have been impressive. Unfortunately, fibrotic diseases are an important cause of morbidity and mortality worldwide. We look forward to the continued collaboration and adding inferential search to further accelerate our mission to deliver transformative therapies for patients with fibrotic diseases.”
